Uveitis Secondary to Autoimmune Disease

Overview

Uveitis is inflammation of the uvea, the middle layer of the eye that includes the iris, ciliary body, and choroid. When the inflammation is triggered by an underlying autoimmune disorder—such as ankylosing spondylitis, Behçet’s disease, sarcoidosis, or inflammatory bowel disease—it is termed **uveitis secondary to autoimmune disease**.

• Who it affects: Adults 20‑50 years are most commonly affected, but children with juvenile idiopathic arthritis (JIA) also develop this type of uveitis.
• Prevalence: Uveitis accounts for roughly 10‑15 % of all blindness worldwide. In the United States, an estimated 770,000 people have some form of uveitis, and up to 30 % of those cases are linked to an autoimmune condition (NIH, 2022).

The disease can be unilateral (one eye) or bilateral (both eyes) and may present as acute, recurrent, or chronic inflammation. Early recognition is essential because permanent vision loss can occur within weeks if left untreated.

Symptoms

Symptoms develop gradually or suddenly, depending on the underlying autoimmune activity. Common signs include:

• Redness: Often described as a “bloodshot” eye, usually affecting the sclera near the iris.
• Eye pain: Dull ache or sharp pain, especially with eye movement.
• Photophobia: Heightened sensitivity to light.
• Blurred or decreased vision: May affect near or distance vision and can fluctuate.
• Floaters: Small, dark specks or strings drifting across the visual field.
• Headache: Often associated with painful eye movement.
• Seeing halos: Colored rings around lights, especially at night.
• Dry eye sensation: A gritty feeling despite normal tear production.
• Eye swelling: Lid edema or conjunctival swelling.

Because many autoimmune diseases have systemic manifestations (joint pain, skin lesions, gastrointestinal symptoms), patients may notice eye symptoms in conjunction with flares of their primary disease.

Causes and Risk Factors

Pathophysiology

Autoimmune‑mediated uveitis occurs when the body’s immune system mistakenly attacks ocular antigens. T‑cells, cytokines (e.g., TNF‑α, IL‑6), and auto‑antibodies infiltrate the uveal tissue, leading to vasculitis, breakdown of the blood‑ocular barrier, and tissue damage.

Common Autoimmune Triggers

• Ankylosing spondylitis – HLA‑B27 positivity is a strong predictor; up to 40 % develop acute anterior uveitis.
• Behçet’s disease – Characterized by recurrent oral/genital ulcers; ocular involvement in >70 % of patients.
• Sarcoidosis – Non‑caseating granulomas can involve any uveal segment.
• Inflammatory bowel disease (IBD) – Crohn’s and ulcerative colitis are linked to intermediate or posterior uveitis.
• Juvenile idiopathic arthritis (JIA) – Particularly the oligoarticular subtype; risk of chronic anterior uveitis is 10‑20 %.
• Systemic lupus erythematosus (SLE) – May cause diffuse retinal vasculitis alongside uveitis.

Risk Factors

• Positive HLA‑B27 status
• Family history of autoimmune disease
• Smoking (increases systemic inflammation)
• Female sex for JIA‑related uveitis; male sex for HLA‑B27‑associated disease
• Uncontrolled systemic disease activity

Diagnosis

Accurate diagnosis requires a combination of clinical exam, imaging, and laboratory work‑up to confirm uveitis and identify the autoimmune source.

Ophthalmic Examination

• Slit‑lamp biomicroscopy: Reveals cells and flare in the anterior chamber, keratic precipitates, posterior synechiae, or granulomatous lesions.
• Fundoscopy (indirect ophthalmoscopy): Detects vitritis, retinal infiltrates, choroidal lesions, or optic disc edema.
• Intraocular pressure (IOP) measurement: Elevated IOP may indicate secondary glaucoma.

Imaging Studies

• Optical Coherence Tomography (OCT): Provides cross‑sectional images of retina and choroid, useful for macular edema.
• Fluorescein Angiography (FA): Highlights retinal vasculitis and leakage.
• Indocyanine Green Angiography (ICGA):** Better for choroidal inflammation.

Laboratory Tests

• Complete blood count, ESR, CRP – markers of systemic inflammation.
• Autoimmune panel: HLA‑B27, ANA, RF, anti‑CCP, ACE levels (sarcoidosis), and specific antibodies for Behçet’s (pathergy test) or IBD.
• Infectious work‑up (e.g., syphilis, TB, Lyme) to rule out mimickers.

Systemic Evaluation

Collaboration with a rheumatologist, dermatologist, or gastroenterologist is often required to establish the underlying autoimmune diagnosis and assess disease activity.

Treatment Options

Treatment aims to suppress ocular inflammation, preserve vision, and control the systemic autoimmune disease.

First‑Line Medications

• Topical corticosteroids: Prednisolone acetate 1 % drops hourly, then tapered. Effective for anterior uveitis.
• Cycloplegic agents: Atropine or cyclopentolate to prevent posterior synechiae and relieve pain.

Systemic Therapy

• Oral corticosteroids: Prednisone 0.5‑1 mg/kg for severe anterior or intermediate uveitis; taper based on response.
• Immunomodulatory (non‑biologic) agents:
  • Methotrexate 15‑25 mg weekly
  • Mycophenolate mofetil 1‑2 g twice daily
  • Azathioprine 2‑2.5 mg/kg
  Useful for chronic or steroid‑sparing therapy.
• Biologic agents: Targeted cytokine inhibition.
  • TNF‑α inhibitors (adalimumab, infliximab) – first‑line biologic for Behçet’s, ankylosing spondylitis‑related uveitis.
  • IL‑6 inhibitor (tocilizumab) – effective for refractory posterior uveitis.
  • IL‑1 blocker (anakinra) – occasional use in Behçet’s.

Local Injections & Procedures

• Periocular (sub‑Tenon) corticosteroid injection: Triamcinolone acetonide 40 mg for intermediate/posterior disease.
• Intravitreal injection: Dexamethasone implant (Ozurdex) or anti‑VEGF agents when macular edema is present.
• Laser photocoagulation: For ischemic retinal areas or neovascularization.

Lifestyle & Supportive Measures

• Protect eyes from bright light (sunglasses with UV protection).
• Use artificial tears for dryness.
• Adhere to a Mediterranean‑style diet rich in omega‑3 fatty acids, which may modestly reduce systemic inflammation.
• Quit smoking and limit alcohol, as both can worsen autoimmune activity.
• Regular exercise improves overall immune regulation.

Living with Uveitis Secondary to Autoimmune Disease

Daily Management Tips

1. Medication adherence: Use a daily log or phone reminders; never stop steroids abruptly.
2. Follow‑up schedule: Initial visits weekly, then every 1‑3 months once stable; more frequent if symptoms recur.
3. Monitor vision: Perform a simple “Amsler grid” test at home; report new distortion immediately.
4. Protect your eyes: Wear wrap‑around sunglasses outdoors and safety goggles during sports.
5. Manage systemic disease: Keep rheumatology appointments, track flares, and report any new joint or skin changes.
6. Stress reduction: Chronic inflammation is stress‑sensitive; meditation, yoga, or counseling can be beneficial.
7. Vaccinations: Stay up‑to‑date (influenza, COVID‑19, pneumococcal) but discuss live vaccines with your specialist if you’re on biologics.

Psychosocial Support

Living with chronic eye inflammation can cause anxiety about vision loss. Support groups (e.g., Uveitis Foundation) and counseling can improve quality of life.

Prevention

While you cannot prevent the autoimmune disease itself, you can lower the risk of uveitis flares:

• Control systemic disease activity: Tight rheumatologic control is the single most effective preventive measure (Mayo Clinic, 2023).
• Regular ophthalmic screening: Patients with known HLA‑B27, Behçet’s, or JIA should have eye exams at least every 6‑12 months.
• Prompt treatment of infections: Respiratory or ocular infections can trigger flares.
• Healthy lifestyle: Balanced diet, regular exercise, adequate sleep, and smoking cessation.

Complications

If inflammation is uncontrolled, the following complications can develop and may lead to permanent vision loss:

• Glaucoma: Steroid‑induced or inflammatory; damages optic nerve.
• Cataract formation: Particularly posterior subcapsular cataracts from chronic steroid use.
• Macular edema: Fluid accumulation in the central retina, causing central vision loss.
• Epiretinal membrane or proliferative vitreoretinopathy: Scar tissue on the retina.
• Retinal detachment: Rare but vision‑threatening.
• Band keratopathy or corneal ulcers: Surface complications from chronic inflammation.
• Permanent vision loss: Reported in up to 8 % of chronic cases when treatment delays exceed 3 months (NEI, 2022).

When to Seek Emergency Care

References

• Mayo Clinic. “Uveitis: Diagnosis and Treatment.” Updated 2023.
• Centers for Disease Control and Prevention. “Uveitis and Autoimmune Disease.” 2022.
• National Institutes of Health (NIH). “Uveitis Statistics.” 2022.
• World Health Organization. “Global Burden of Vision Impairment.” 2021.
• Cleveland Clinic. “Autoimmune Uveitis Management.” 2023.
• Jabs DA, et al. “Standardization of Uveitis Nomenclature (SUN) Working Group.” *Ophthalmology*. 2020.